Close Menu

Enigma Diagnostics

The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.

The UK-based firm is selling technology underlying its point-of-care molecular diagnostics platform, the Enigma MiniLab.

The Enigma MiniLab runs single-tube multiplex panels at the point of care, with a lower price point than other commercially available syndromic panel platforms. 

NEW YORK (GenomeWeb) – Enigma Diagnostics and Beijing Leadman Biochemistry today announced a joint venture agreement aimed at bringing Enigma's point-of-care molecular diagnostic system to China.

NEW YORK (GenomeWeb) — Researchers at Johns Hopkins University have performed the first validation of the Cepheid Xpert Flu assay in a population of emergency room patients with acute undifferentiated respiratory illness.

NEW YORK (GenomeWeb) – Enigma Diagnostics today said that it will collaborate with China’s National Institute for Communicable Disease Control and Prevention on the development of rapid molecular diagnostics for infectious disease pathogens.

NEW YORK (GenomeWeb News) – Enigma Diagnostics today announced a second grant from the UK's Technology Strategy Board to further develop the company's multidrug-resistant tuberculosis (MDR-TB) test on its Enigma Mini Laboratory system.

Enigma Diagnostics said this week that it has received CE IVD marking for its Enigma ML system and first assay, a combined molecular test for influenza A/B and respiratory syncytial virus.

BioFire Diagnostics said this week that it has commenced clinical and analytical studies to evaluate its FilmArray Gastrointestinal Panel with plans to seek both CE IVD marking and US Food and Drug Administration clearance.

NEW YORK (GenomeWeb News) – Enigma Diagnostics this week said that it has received a Biomedical Catalyst grant from the UK government to support further development of multiplexed PCR assays using the firm's ResonSense probing technology.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.